Jean-Yves Blay
Direktor/Vorstandsmitglied bei INNATE PHARMA
Vermögen: 118 $ am 30.04.2024
Profil
Jean-Yves Blay is currently an Independent Director at Transgene SA since 2022, the General Director at Centre Léon Bérard Lyon et Rhône-Alpes since 2014, and an Independent Member-Supervisory Board at Innate Pharma SA since 2017.
Previously, he served as the President of the European Organisation for Research & Treatment of Cancer from 2009 to 2012 and as the President of UNICANCER from 2019 to 2022.
He also held the position of Secretary-Oncology Commission at Académie Nationale de Médecine FCP.
Dr. Blay obtained his doctorate degree from Université Claude Bernard Lyon 1 in 1994.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
INNATE PHARMA SA CLASS A
0,00% | 31.12.2022 | 50 ( 0,00% ) | 118 $ | 30.04.2024 |
Aktive Positionen von Jean-Yves Blay
Unternehmen | Position | Beginn |
---|---|---|
INNATE PHARMA | Direktor/Vorstandsmitglied | 13.12.2017 |
TRANSGENE | Direktor/Vorstandsmitglied | 25.05.2022 |
Centre Léon Bérard Lyon et Rhône-Alpes | Vorstandsvorsitzender | 01.01.2014 |
Ehemalige bekannte Positionen von Jean-Yves Blay
Unternehmen | Position | Ende |
---|---|---|
UNICANCER
UNICANCER Hospital/Nursing ManagementHealth Services UNICANCER is a French hospital network that is dedicated to fighting against cancer. The private company is based in Paris, France. It is the only national hospital federation that is solely focused on oncology. The network comprises of 18 French cancer centers (CLCC) and a private non-profit health establishment. The CLCCs take care of almost 530,000 patients annually. UNICANCER is also a leading academic promoter of clinical trials in oncology in Europe, with 106 active clinical trials promoted and nearly 7,600 patients included. | Präsident | 01.01.2022 |
European Organisation for Research & Treatment of Cancer | Präsident | 01.01.2012 |
Académie Nationale de Médecine FCP | Corporate Officer/Principal | - |
Ausbildung von Jean-Yves Blay
Université Claude Bernard Lyon 1 | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
INNATE PHARMA | Health Technology |
TRANSGENE | Health Technology |
Private Unternehmen | 4 |
---|---|
Centre Léon Bérard Lyon et Rhône-Alpes | |
Académie Nationale de Médecine FCP | Commercial Services |
European Organisation for Research & Treatment of Cancer | |
UNICANCER
UNICANCER Hospital/Nursing ManagementHealth Services UNICANCER is a French hospital network that is dedicated to fighting against cancer. The private company is based in Paris, France. It is the only national hospital federation that is solely focused on oncology. The network comprises of 18 French cancer centers (CLCC) and a private non-profit health establishment. The CLCCs take care of almost 530,000 patients annually. UNICANCER is also a leading academic promoter of clinical trials in oncology in Europe, with 106 active clinical trials promoted and nearly 7,600 patients included. | Health Services |